Molecular and Cellular Basis for Anti-Amyloid Therapy in Alzheimer Disease
Lippincott Williams & Wilkins
Faculty of Computing, Health and Science
School of Exercise, Biomedical and Health Science
AIzheimer disease (AD) is characterized by clinical evidence of cognitive failure in association with cerebral amyloidosis, as well as cerebral intraneuronal neurofibrillary pathology, neuronal and synaptic loss, and neurotransmitter deficits. The cerebral amyloid of AD is deposited around meningeal and cerebral vessels, as well as in gray matter. In gray matter, the deposits are multifocal, coalescing into miliary structures known as plaques. Parenchymal amyloid plaques are distributed in brain in a characteristic fashion, differentially affecting the cerebrum and hippocampus, while largely sparing the basal ganglia, thalamus, spinal cord, and hindbrain.